1. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials1. Issue 10 (12th August 2018) Authors: Hagins, D; Orkin, C; Daar, ES; Mills, A; Brinson, C; DeJesus, E; Post, FA; Morales‐Ramirez, J; Thompson, M; Osiyemi, O; Rashbaum, B; Stellbrink, H‐J; Martorell, C; Liu, H; Liu, Y‐P; Porter, D; Collins, SE; SenGupta, D; Das, M Journal: HIV medicine Issue: Volume 19:Issue 10(2018) Page Start: 724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗